Daito Pharmaceutical Co.,Ltd. announced that it expects to receive ¥13.351 million in funding from Daiwa Securities Co., Ltd., Investment Arm
September 12, 2021
Share
Daito Pharmaceutical Co.,Ltd. announced a private placement of 13,000 2nd stock acquisition rights at issue price of ¥1,027 per stock acquisition right for gross proceeds of ¥13,351,000 on September 13, 2021. The transaction will include participation from returning investor, Daiwa Securities Co., Ltd., Investment Arm. The rights can be exercisable to purchase common shares of the company at an exercise price of ¥3,655 per share. The company shall issue securities pursuant to third-party allotment method. The rights can be exercised from September 30, 2021 to September 30, 2024. The transaction will close on September 29, 2021. The transaction has been approved by the board of directors of the company.
Daito Pharmaceutical Co., Ltd. is a Japan-based company mainly engaged in the pharmaceutical ingredients and formulation business, as well as healthy food. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.
DAITO PHARMACEUTICAL CO.,LTD. 
